Bank of Montreal
BCRX icon

Bank of Montreal’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bank of Montreal’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,600
Closed -$244K – 3792
2022
Q4 		$244K Hold
19,600
– – ﹤0.01% 3045
2022
Q3 		$253 Hold
19,600
– – ﹤0.01% 3047
2022
Q2 		$206 Hold
19,600
– – ﹤0.01% 3252
2022
Q1 		$322K Buy
+19,600
New +$314K ﹤0.01% 3148
2021
Q4 		– Sell
-19,600
Closed -$301K – 3506
2021
Q3 		$301K Buy
+19,600
New +$309K ﹤0.01% 3131

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of Montreal's BCRX Position: Q4 2025 in Review

Bank of Montreal sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 12,862 shares — an estimated $97.6K sold.

Bank of Montreal first reported a position in BCRX in Q4 2013 and held it in 47 quarters. The position peaked at $1.15M in Q3 2021. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Bank of Montreal reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bank of Montreal sold 12,862 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $97.6K.
  • Bank of Montreal first reported a position in BioCryst Pharmaceuticals in Q4 2013 and held it in 47 quarters.
  • Bank of Montreal's BioCryst Pharmaceuticals position peaked at $1.15M in Q3 2021.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Bank of Montreal's 13F filing for Q4 2025, filed 12 Feb 2026.